Argentina's ANMAT streamlines regulatory approval process for biological drugs

Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT) has reduced administrative requirements for the development and marketing of biological pharmaceuticals. This regulatory shift aims to lower barriers for laboratories, though the specific impact on safety oversight protocols remains to be detailed.